• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Dec. 27 Suven Life Sciences Ltd has obtained a product patent from the US Patent Office for the class of selective Serotonin receptor affinity compounds discovered by Suven and being developed as therapeutic agents.

The patent (US 7,297,711) was the first product patent granted in the US for the Hyderabad-based company. According to the invention 711 patent disclosure, the compounds are useful in the treatment of neurodegenerative disorders like Alzheimer’s, Parkinson, Schizophrenia, and Huntington’s.

“We are very pleased by the issuance of this patent to Suven by US Patent office for our drug candidates that are being developed for CNS (central nervous system) disorders which targets a $18-billion potential market opportunity,” Mr Venkat Jasti, CEO of Suven, said in a release.

Suven has so far filed 29 product patent applications covering more than 145 countries, out of which five patents had been granted in various countries, according to a release.

Several other patent applications from Suven Discovery Research had completed the administrative and technical diligence from the patent offices from major countries and the patents would be granted shortly, the release added.

More Stories on : IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
More companies take QIP route to raise funds

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line